Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan
The molecular background of the Ca2+-sensitizing effect of levosimendan relates to its
specific interaction with the Ca2+-sensor troponin C molecule in the cardiac myofilaments …
specific interaction with the Ca2+-sensor troponin C molecule in the cardiac myofilaments …
Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome
J Schumann, EC Henrich, H Strobl… - Cochrane Database …, 2018 - cochranelibrary.com
Background Cardiogenic shock (CS) and low cardiac output syndrome (LCOS) as
complications of acute myocardial infarction (AMI), heart failure (HF) or cardiac surgery are …
complications of acute myocardial infarction (AMI), heart failure (HF) or cardiac surgery are …
[PDF][PDF] 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
5.2. 1. Ocena funkcji skurczowej lewej komory...................................... 1052 5.2. 2. Ocena
funkcji rozkurczowej lewej komory...................................... 1052 5.2. 3. Ocena funkcji prawej …
funkcji rozkurczowej lewej komory...................................... 1052 5.2. 3. Ocena funkcji prawej …
[PDF][PDF] Guía ESC 2016 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica
Se recomienda a los profesionales de la salud que tengan en consideración la presente
guía de la ESC en la toma de decisiones clínicas en su ejercicio diario, así como en la …
guía de la ESC en la toma de decisiones clínicas en su ejercicio diario, así como en la …
Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies
Objective: Catecholaminergic inotropes have a place in the management of low output
syndrome and decompensated heart failure but their effect on mortality is debated …
syndrome and decompensated heart failure but their effect on mortality is debated …
[HTML][HTML] Levosimendan: current data, clinical use and future development
MS Nieminen, S Fruhwald, LMA Heunks… - Heart, lung and …, 2013 - ncbi.nlm.nih.gov
Levosimendan is an inodilator indicated for the short-term treatment of acutely
decompensated severe chronic heart failure, and in situations where conventional therapy is …
decompensated severe chronic heart failure, and in situations where conventional therapy is …
Wytyczne ESC dotyczace diagnostyki i leczenia ostrej i przewlekłej niewydolności serca w 2016 roku
Abstract Stowarzyszenia ESC: Acute Cardiovascular Care Association (ACCA), European
Association for Cardiovascular Prevention and Rehabilitation (EACPR), European …
Association for Cardiovascular Prevention and Rehabilitation (EACPR), European …
Dobutamine for patients with severe heart failure: a systematic review and meta-analysis of randomised controlled trials
CL Tacon, J McCaffrey, A Delaney - Intensive care medicine, 2012 - Springer
Purpose Dobutamine is recommended for patients with severe heart failure; however
uncertainty exists as to its effect on mortality. This study aims to critically review the literature …
uncertainty exists as to its effect on mortality. This study aims to critically review the literature …
Cardiac inotropes: current agents and future directions
G Hasenfuss, JR Teerlink - European heart journal, 2011 - academic.oup.com
Intrinsic inotropic stimulation of the heart is central to the regulation of cardiovascular
function, and exogenous inotropic therapies have been used clinically for decades …
function, and exogenous inotropic therapies have been used clinically for decades …
[HTML][HTML] Levosimendan meta-analyses: Is there a pattern in the effect on mortality?
P Pollesello, J Parissis, M Kivikko, VP Harjola - International journal of …, 2016 - Elsevier
Background Levosimendan is an inodilator developed for treatment of acute heart failure
and other cardiac conditions where the use of an inodilator is considered appropriate …
and other cardiac conditions where the use of an inodilator is considered appropriate …